| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Clayton Center for Ocular Oncology, Childrens Hospital Los Angeles, Los Angeles, California 90027 [A. F., K. F. v. T., N. R., C. J. G.], and Departments of Pediatrics [C. J. G., M. A. S.], Radiation Oncology [C. J. G.], Medicine [P. S. G.], Pathology [P. S. G.], and Surgery [M. A. S.], Keck School of Medicine, University of Southern California, Los Angeles, California 90033
Photodynamic therapy (PDT) is a promising cancer treatment that induces
localized tumor destruction via the photochemical generation of
cytotoxic singlet oxygen. PDT-mediated oxidative stress elicits direct
tumor cell damage as well as microvascular injury within exposed
tumors. Reduction in vascular perfusion associated with PDT-mediated
microvascular injury produces tumor tissue hypoxia. Using a
transplantable BA mouse mammary carcinoma, we show that
Photofrin-mediated PDT induced expression of the hypoxia-inducible
factor-1
(HIF-1
) subunit of the heterodimeric HIF-1 transcription
factor and also increased protein levels of the HIF-1 target gene,
vascular endothelial growth factor (VEGF), within treated tumors.
HIF-1
and VEGF expression were also observed following tumor
clamping, which was used as a positive control for inducing tissue
hypoxia. PDT treatment of BA tumor cells grown in culture resulted in a
small increase in VEGF expression above basal levels, indicating that
PDT-mediated hypoxia and oxidative stress could both be involved in the
overexpression of VEGF. Tumor-bearing mice treated with combined
antiangiogenic therapy (IM862 or EMAP-II) and PDT had improved
tumoricidal responses compared with individual treatments. We also
demonstrated that PDT-induced VEGF expression in tumors decreased when
either IM862 or EMAP-II was included in the PDT treatment protocol. Our
results indicate that combination procedures using antiangiogenic
treatments can improve the therapeutic effectiveness of PDT.
This article has been cited by other articles:
![]() |
M. Ju, C. Mailhos, J. Bradley, T. Dowie, M. Ganley, G. Cook, P. Calias, N. Lange, A. P. Adamis, D. T. Shima, et al. Simultaneous but Not Prior Inhibition of VEGF165 Enhances the Efficacy of Photodynamic Therapy in Multiple Models of Ocular Neovascularization Invest. Ophthalmol. Vis. Sci., February 1, 2008; 49(2): 662 - 670. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ferrario, N. Rucker, S. Wong, M. Luna, and C. J. Gomer Survivin, a Member of the Inhibitor of Apoptosis Family, Is Induced by Photodynamic Therapy and Is a Target for Improving Treatment Response Cancer Res., May 15, 2007; 67(10): 4989 - 4995. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mitra, S. E. Cassar, D. J. Niles, J. A. Puskas, J. G. Frelinger, and T. H. Foster Photodynamic therapy mediates the oxygen-independent activation of hypoxia-inducible factor 1{alpha} Mol. Cancer Ther., December 1, 2006; 5(12): 3268 - 3274. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Kosharskyy, N. Solban, S. K. Chang, I. Rizvi, Y. Chang, and T. Hasan A Mechanism-Based Combination Therapy Reduces Local Tumor Growth and Metastasis in an Orthotopic Model of Prostate Cancer. Cancer Res., November 15, 2006; 66(22): 10953 - 10958. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Solban, S. K. Pal, S. K. Alok, C. K. Sung, and T. Hasan Mechanistic Investigation and Implications of Photodynamic Therapy Induction of Vascular Endothelial Growth Factor in Prostate Cancer Cancer Res., June 1, 2006; 66(11): 5633 - 5640. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ferrario, A. M. Fisher, N. Rucker, and C. J. Gomer Celecoxib and NS-398 Enhance Photodynamic Therapy by Increasing In vitro Apoptosis and Decreasing In vivo Inflammatory and Angiogenic Factors Cancer Res., October 15, 2005; 65(20): 9473 - 9478. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Noy, D. T. Scadden, J. Lee, B. J. Dezube, D. Aboulafia, A. Tulpule, S. Walmsley, and P. Gill Angiogenesis Inhibitor IM862 Is Ineffective Against AIDS-Kaposi's Sarcoma in a Phase III Trial, but Demonstrates Sustained, Potent Effect of Highly Active Antiretroviral Therapy: From the AIDS Malignancy Consortium and IM862 Study Team J. Clin. Oncol., February 10, 2005; 23(5): 990 - 998. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Schwarz, Z. Wan, J. Liu, and M. K. Lee Epithelial-Mesenchymal Interactions Are Linked to Neovascularization Am. J. Respir. Cell Mol. Biol., June 1, 2004; 30(6): 784 - 792. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ferrario, C. F. Chantrain, K. von Tiehl, S. Buckley, N. Rucker, D. R. Shalinsky, H. Shimada, Y. A. DeClerck, and C. J. Gomer The Matrix Metalloproteinase Inhibitor Prinomastat Enhances Photodynamic Therapy Responsiveness in a Mouse Tumor Model Cancer Res., April 1, 2004; 64(7): 2328 - 2332. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Makowski, T. Grzela, J. Niderla, M. Lazarczyk, P. Mroz, M. Kopee, M. Legat, K. Strusinska, K. Koziak, D. Nowis, et al. Inhibition of Cyclooxygenase-2 Indirectly Potentiates Antitumor Effects of Photodynamic Therapy in Mice Clin. Cancer Res., November 1, 2003; 9(14): 5417 - 5422. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Schmidt-Erfurth, U. Schlotzer-Schrehard, C. Cursiefen, S. Michels, A. Beckendorf, and G. O. H. Naumann Influence of Photodynamic Therapy on Expression of Vascular Endothelial Growth Factor (VEGF), VEGF Receptor 3, and Pigment Epithelium-Derived Factor Invest. Ophthalmol. Vis. Sci., October 1, 2003; 44(10): 4473 - 4480. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. J. G. J. Dolmans, A. Kadambi, J. S. Hill, K. R. Flores, J. N. Gerber, J. P. Walker, I. H. M. B. Rinkes, R. K. Jain, and D. Fukumura Targeting Tumor Vasculature and Cancer Cells in Orthotopic Breast Tumor by Fractionated Photosensitizer Dosing Photodynamic Therapy Cancer Res., August 1, 2002; 62(15): 4289 - 4294. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ferrario, K. von Tiehl, S. Wong, M. Luna, and C. J. Gomer Cyclooxygenase-2 Inhibitor Treatment Enhances Photodynamic Therapy-mediated Tumor Response Cancer Res., July 15, 2002; 62(14): 3956 - 3961. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. J. G. J. Dolmans, A. Kadambi, J. S. Hill, C. A. Waters, B. C. Robinson, J. P. Walker, D. Fukumura, and R. K. Jain Vascular Accumulation of a Novel Photosensitizer, MV6401, Causes Selective Thrombosis in Tumor Vessels after Photodynamic Therapy Cancer Res., April 1, 2002; 62(7): 2151 - 2156. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Luna, X. Chen, S. Wong, J. Tsui, N. Rucker, A. S. Lee, and C. J. Gomer Enhanced Photodynamic Therapy Efficacy with Inducible Suicide Gene Therapy Controlled by the grp Promoter Cancer Res., March 1, 2002; 62(5): 1458 - 1461. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Zheng, M. A. Schwarz, S. Lee, U. Kumaraguru, and B. T. Rouse Control of Stromal Keratitis by Inhibition of Neovascularization Am. J. Pathol., September 1, 2001; 159(3): 1021 - 1029. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Peng, T. Warloe, J. Moan, A. Godal, F. Apricena, K.-E. Giercksky, and J. M. Nesland Antitumor Effect of 5-Aminolevulinic Acid-mediated Photodynamic Therapy Can Be Enhanced by the Use of a Low Dose of Photofrin in Human Tumor Xenografts Cancer Res., August 1, 2001; 61(15): 5824 - 5832. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. R. Zhang and M. A. Schwarz Pro-EMAP II is not primarily cleaved by caspase-3 and -7 Am J Physiol Lung Cell Mol Physiol, June 1, 2002; 282(6): L1239 - L1244. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |